Tonix Pharmaceuticals Holding Corp. recently highlighted its current clinical and commercial activities in a presentation. The company is focused on developing therapeutics for conditions involving pain, neurology, psychiatry, and addiction, as well as areas like immunology, infectious diseases, and rare diseases. Their key clinical program, TNX-102 SL, is being developed for fibromyalgia, with an FDA decision on marketing authorization expected by August 15, 2025. The program has been granted FDA Fast Track Designation, and potential product launch is anticipated for 2025. Additionally, Tonix is advancing TNX-1500, an anti-CD40L monoclonal antibody, for organ transplant rejection and autoimmune conditions, having completed a Phase 1 study. The company is also marketing products like Zembrace® and Tosymra® for acute migraine treatment. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.